Treatment of metastatic medullary thyroid cancer with vandetanib: Need to stratify patients on basis of calcitonin doubling time

Journal of Clinical Oncology

Volumn 30, Issue 17, 2012, Pages 2165-

  Chatal, Jean François ^a   Kraeber Bodéré, Françoise ^b   Goldenberg, David M ^c   Barbet, Jacques ^d  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^d Team 12   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; VANDETANIB;

CANCER GROWTH; CANCER PROGNOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; LETTER; LIFE EXPECTANCY; METASTASIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

FEMALE; HUMANS; MALE; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84863922163     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.3160     Document Type: Letter

References (4)

1. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, doubleblind phase III trial. J Clin Oncol 30:134-141, 2012
2. Solomon B, Rischin D: Progress in molecular targeted therapy for thyroid cancer: Vandetanib in medullary thyroid cancer. J Clin Oncol 30:119-121, 2012
3. Barbet J, Campion L, Kraeber-Bodéré F, et al: Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084, 2005 (Pubitemid 41606528)
4. Chatal JF, Campion L, Kraeber-Bodéré F, et al: Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705-1711, 2006 (Pubitemid 46622142)